drugset
Drugs / ZW251
last change Oct 2025 re-read 3 minutes ago

ZW251

targets GPC3

Developed for
germ cell tumor · hepatocellular carcinoma · non-small cell squamous lung carcinoma
Investigated by
Zymeworks BC Inc.

Trials 1

today NCT07164313 · Ph 1
20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07164313 Oct 2025 → Sep 2027 expected germ cell tumor, hepatocellular carcinoma, non-small cell squamous lung carcinoma Zymeworks BC Inc. Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 4

DateIssuerRelease
2025-07-28 Zymeworks BC Inc. Regulatory Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate zymeworks.com ↗
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
2024-10-25 Zymeworks BC Inc. Results Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference zymeworks.com ↗
In NHP studies, ZW251 displayed significant tolerability at doses up to 120 mg/kg.
2024-09-18 Zymeworks BC Inc. Results Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference zymeworks.com ↗
2023-04-18 Zymeworks BC Inc. Results Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting zymeworks.com ↗
ZW251 exhibits desired target-mediated activity in vitro and robust anti-tumor activity in PDX models

All press releases naming this drug 4 releases

DateIssuerRelease

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ZW251 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07164313 ↗
Route Intravenous “Administered intravenously” NCT07164313 ↗
Target GPC3 “targeting glypican-3 (GPC3)” NCT07164313 ↗